Literature DB >> 27521444

Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas.

Pedro R Lowenstein1, Maria G Castro2.   

Abstract

A novel approach to immunization against glioma tumors is described. Immunization against 11 antigens expressed in malignant brain tumors elicits responses to one or more antigens in a large percentage of patients. This novel approach suggests that it could be extended to a phase III trial. Clin Cancer Res; 22(19); 4760-2. ©2016 AACRSee related article by Rampling et al., p. 4776. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27521444      PMCID： PMC5076016          DOI： 10.1158/1078-0432.CCR-16-1477

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.

Authors:  Valérie Dutoit; Christel Herold-Mende; Norbert Hilf; Oliver Schoor; Philipp Beckhove; Judith Bucher; Katharina Dorsch; Sylvia Flohr; Jens Fritsche; Peter Lewandrowski; Jennifer Lohr; Hans-Georg Rammensee; Stefan Stevanovic; Claudia Trautwein; Verona Vass; Steffen Walter; Paul R Walker; Toni Weinschenk; Harpreet Singh-Jasuja; Pierre-Yves Dietrich
Journal:  Brain       Date:  2012-03-14       Impact factor: 13.501

Review 2.  Immune Checkpoint Blockade in Cancer Therapy.

Authors:  Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

3.  Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

Authors:  Mrinal M Gounder; Lakshmi Nayak; Solmaz Sahebjam; Alona Muzikansky; Armando J Sanchez; Serena Desideri; Xiaobu Ye; S Percy Ivy; L Burt Nabors; Michael Prados; Stuart Grossman; Lisa M DeAngelis; Patrick Y Wen
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

Review 4.  Overview of current immunotherapeutic strategies for glioma.

Authors:  Anda-Alexandra Calinescu; Neha Kamran; Gregory Baker; Yohei Mineharu; Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 5.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 6.  Glioblastoma.

Authors:  Hans-Georg Wirsching; Evanthia Galanis; Michael Weller
Journal:  Handb Clin Neurol       Date:  2016

7.  Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

Authors:  Timothy F Cloughesy; Joseph Landolfi; Daniel J Hogan; Stephen Bloomfield; Bob Carter; Clark C Chen; J Bradley Elder; Steven N Kalkanis; Santosh Kesari; Albert Lai; Ian Y Lee; Linda M Liau; Tom Mikkelsen; Phioanh Leia Nghiemphu; David Piccioni; Tobias Walbert; Alice Chu; Asha Das; Oscar R Diago; Dawn Gammon; Harry E Gruber; Michelle Hanna; Douglas J Jolly; Noriyuki Kasahara; David McCarthy; Leah Mitchell; Derek Ostertag; Joan M Robbins; Maria Rodriguez-Aguirre; Michael A Vogelbaum
Journal:  Sci Transl Med       Date:  2016-06-01       Impact factor: 17.956

8.  Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors.

Authors:  R Rampling; G Cruickshank; A D Lewis; S A Fitzsimmons; P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-06-15       Impact factor: 7.038

Review 9.  Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.

Authors:  Paul E Hughes; Sean Caenepeel; Lawren C Wu
Journal:  Trends Immunol       Date:  2016-05-20       Impact factor: 16.687

10.  HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Authors:  James F Curtin; Naiyou Liu; Marianela Candolfi; Weidong Xiong; Hikmat Assi; Kader Yagiz; Matthew R Edwards; Kathrin S Michelsen; Kurt M Kroeger; Chunyan Liu; A K M Ghulam Muhammad; Mary C Clark; Moshe Arditi; Begonya Comin-Anduix; Antoni Ribas; Pedro R Lowenstein; Maria G Castro
Journal:  PLoS Med       Date:  2009-01-13       Impact factor: 11.069
  10 in total
  1 in total

Review 1.  Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).

Authors:  Alice Giotta Lucifero; Sabino Luzzi
Journal:  Brain Sci       Date:  2021-03-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.